Literature DB >> 23743311

Elevated IP-10 and IL-6 from bronchoalveolar lavage cells are biomarkers of non-cavitary tuberculosis.

A Nolan1, R Condos, M L Huie, R Dawson, K Dheda, E Bateman, W N Rom, M D Weiden.   

Abstract

BACKGROUND: Active TB disease can destroy lung parenchyma leading to cavities. Immune responses that predispose or protect individuals from lung damage during TB are poorly defined.
OBJECTIVE: To sample lung immune cells and assay bronchoalveolar lavage (BAL) cell cytokine production.
DESIGN: Enrolled subjects (n = 73) had bilateral infiltrates and underwent BAL.
RESULTS: All had sputum culture demonstrating Mycobacterium tuberculosis and 22/73 (30%) had cavities on their chest radiograph. Those with cavities at presentation had a higher percentage of polymorphonuclear neutrophils (PMN) in BAL as well as lower inducible protein (IP) 10 (P < 0.01) and interleukin (IL) 6 (P = 0.013) in BAL cell supernatants compared to those without cavities. There was no correlation between cavities and other BAL or serum cytokines. IP-10 was negatively associated with BAL PMN. IP-10 and IL-6 expression above median reduces the odds of cavities by 79% and 78% in logistic regression models. IP-10 and IL-6 clustered with interferon-gamma and tumour necrosis factor-alpha in a principal component analysis, while IL-4 clustered with PMN.
CONCLUSION: Increasing IP-10 and IL-6 production by BAL cells is associated with non-cavitary TB in patients who present with radiographically advanced TB. IP-10 and IL-6 may reflect an effective T-helper 1 immune control pathway for TB, attenuating tuberculous lung destruction.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23743311      PMCID: PMC4050635          DOI: 10.5588/ijtld.12.0610

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  31 in total

1.  Polarization of PPD-specific T-cell response of patients with tuberculosis from Th0 to Th1 profile after successful antimycobacterial therapy or in vitro conditioning with interferon-alpha or interleukin-12.

Authors:  A Marchant; A Amedei; A Azzurri; J Vekemans; M Benagiano; C Tamburini; C Lienhardt; T Corrah; K P McAdam; S Romagnani; M M D'Elios; G Del Prete
Journal:  Am J Respir Cell Mol Biol       Date:  2001-02       Impact factor: 6.914

2.  T lymphocyte phenotypic profile in lung segments affected by cavitary and non-cavitary tuberculosis.

Authors:  G Mazzarella; A Bianco; F Perna; D D'Auria; E Grella; E Moscariello; A Sanduzzi
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

3.  Interferon-gamma inducible protein 10 as a biomarker for active tuberculosis and latent tuberculosis infection in children: a case-control study.

Authors:  Neele Alsleben; Morten Ruhwald; Holger Rüssmann; Florian M Marx; Ulrich Wahn; Klaus Magdorf
Journal:  Scand J Infect Dis       Date:  2011-11-21

4.  IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking.

Authors:  Jennifer H Dufour; Michelle Dziejman; Michael T Liu; Josephine H Leung; Thomas E Lane; Andrew D Luster
Journal:  J Immunol       Date:  2002-04-01       Impact factor: 5.422

5.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Authors:  J Keane; S Gershon; R P Wise; E Mirabile-Levens; J Kasznica; W D Schwieterman; J N Siegel; M M Braun
Journal:  N Engl J Med       Date:  2001-10-11       Impact factor: 91.245

6.  IL-10-producing T cells suppress immune responses in anergic tuberculosis patients.

Authors:  V A Boussiotis; E Y Tsai; E J Yunis; S Thim; J C Delgado; C C Dascher; A Berezovskaya; D Rousset; J M Reynes; A E Goldfeld
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

7.  Type 2 cytokine gene activation and its relationship to extent of disease in patients with tuberculosis.

Authors:  G T Seah; G M Scott; G A Rook
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

8.  Use of genetic profiling in leprosy to discriminate clinical forms of the disease.

Authors:  Joshua R Bleharski; Huiying Li; Christoph Meinken; Thomas G Graeber; Maria-Teresa Ochoa; Masahiro Yamamura; Anne Burdick; Euzenir N Sarno; Manfred Wagner; Martin Röllinghoff; Thomas H Rea; Marco Colonna; Steffen Stenger; Barry R Bloom; David Eisenberg; Robert L Modlin
Journal:  Science       Date:  2003-09-12       Impact factor: 47.728

9.  Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo.

Authors:  Christian Lienhardt; Annalisa Azzurri; Amedeo Amedei; Katherine Fielding; Jackson Sillah; Oumou Y Sow; Boubacar Bah; Marisa Benagiano; Alimou Diallo; Roberto Manetti; Kebba Manneh; Per Gustafson; Steve Bennett; Mario M D'Elios; Keith McAdam; Gianfranco Del Prete
Journal:  Eur J Immunol       Date:  2002-06       Impact factor: 5.532

10.  Recombinant gamma interferon stimulates signal transduction and gene expression in alveolar macrophages in vitro and in tuberculosis patients.

Authors:  Rany Condos; Bindu Raju; Antony Canova; Ben-Yang Zhao; Michael Weiden; William N Rom; Richard Pine
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

View more
  14 in total

Review 1.  Chemokines in tuberculosis: the good, the bad and the ugly.

Authors:  Leticia Monin; Shabaana A Khader
Journal:  Semin Immunol       Date:  2014-10-22       Impact factor: 11.130

Review 2.  Cytokines and Chemokines in Mycobacterium tuberculosis Infection.

Authors:  Racquel Domingo-Gonzalez; Oliver Prince; Andrea Cooper; Shabaana A Khader
Journal:  Microbiol Spectr       Date:  2016-10

3.  IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection.

Authors:  Kristian Tonby; Morten Ruhwald; Dag Kvale; Anne Ma Dyrhol-Riise
Journal:  Sci Rep       Date:  2015-03-18       Impact factor: 4.379

4.  Postprimary Tuberculosis and Macrophage Necrosis: Is There a Big ConNECtion?

Authors:  Ka-Wing Wong; William R Jacobs
Journal:  MBio       Date:  2016-01-12       Impact factor: 7.867

5.  Pulmonary immune responses to Mycobacterium tuberculosis in exposed individuals.

Authors:  Christian Herzmann; Martin Ernst; Christoph Lange; Steffen Stenger; Stefan H E Kaufmann; Norbert Reiling; Tom Schaberg; Lize van der Merwe; Jeroen Maertzdorf
Journal:  PLoS One       Date:  2017-11-10       Impact factor: 3.240

6.  A 3'UTR polymorphism of IL-6R is associated with Chinese pediatric tuberculosis.

Authors:  Chen Shen; Hui Qi; Lin Sun; Jing Xiao; Qing-qin Yin; Wei-wei Jiao; Xi-rong Wu; Jian-ling Tian; Rui Han; A-dong Shen
Journal:  Biomed Res Int       Date:  2014-03-19       Impact factor: 3.411

7.  NF-κB repressing factor inhibits chemokine synthesis by peripheral blood mononuclear cells and alveolar macrophages in active pulmonary tuberculosis.

Authors:  Kuo-Hsiung Huang; Chun-Hua Wang; Kang-Yun Lee; Shu-Min Lin; Chien-Huang Lin; Han-Pin Kuo
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

8.  Analysis of Plasma Cytokine and Chemokine Profiles in Patients with and without Tuberculosis by Liquid Array-Based Multiplexed Immunoassays.

Authors:  Wenjing Xiong; Haiping Dong; Juanjuan Wang; Xiaoming Zou; Qian Wen; Wei Luo; Sudong Liu; Jianchun He; Shaoxi Cai; Li Ma
Journal:  PLoS One       Date:  2016-02-16       Impact factor: 3.240

9.  Immunological recovery in patients with pulmonary tuberculosis after intensive phase treatment.

Authors:  Xuejiao Luo; Furong Wu; Jun Ma; Heping Xiao; Haiyan Cui
Journal:  J Int Med Res       Date:  2018-05-13       Impact factor: 1.671

10.  Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study.

Authors:  Anna Cristina C Carvalho; Gustavo Amorim; Mayla G M Melo; Ana Karla A Silveira; Pedro H L Vargas; Adriana S R Moreira; Michael S Rocha; Alexandra B Souza; María B Arriaga; Mariana Araújo-Pereira; Marina C Figueiredo; Betina Durovni; José R Lapa-E-Silva; Solange Cavalcante; Valeria C Rolla; Timothy R Sterling; Marcelo Cordeiro-Santos; Bruno B Andrade; Elisangela C Silva; Afrânio L Kritski
Journal:  Front Immunol       Date:  2021-07-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.